VEGF (Vascular Endothelial Growth Factor)

VEGF (Vascular Endothelial Growth Factor) is a family of secreted homodimeric glycoproteins — including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF) — that act as the primary drivers of blood and lymphatic vessel formation in both developmental and post-natal contexts. VEGF-A, the founding and most studied family member, signals predominantly through VEGFR2 on vascular endothelial cells to coordinate endothelial proliferation, survival, migration, and vascular permeability.

Why it matters in peptide research

VEGF is the master coordinator of angiogenesis — the growth of new capillaries from existing vessels — which is indispensable for tissue repair, exercise adaptation, and organ regeneration. When tissue is hypoxic, injured, or metabolically stressed, hypoxia-inducible factor-1α (HIF-1α) transcriptionally upregulates VEGF, creating a chemotactic gradient that recruits endothelial cells and circulating progenitors to establish new vascular supply.

The therapeutic implications are broad: insufficient VEGF signaling impairs wound healing, muscle regeneration after injury, and tendon repair; excessive or dysregulated VEGF signaling drives tumor angiogenesis, retinopathy, and pathological vessel leakage. For peptide researchers, modulating VEGF expression — either upregulating it in repair contexts or interpreting a compound's angiogenic activity through its VEGF effects — is a fundamental mechanistic consideration.

VEGF also mediates acute vascular permeability changes (the "vascular leak" response): opening of endothelial junctions to allow plasma proteins and immune cells into injured tissue is a critical early step in the inflammatory and repair cascade, and this function is mediated in part by VEGF-driven VE-cadherin phosphorylation and junction disassembly. Understanding this role clarifies why VEGF upregulation early in healing is not synonymous with pathological edema.

Peptides that act on this

• BPC-157 — preclinical evidence for robust VEGF upregulation across multiple injury models (tendon, muscle, gut, bone); proposed to drive angiogenesis through coordinated upregulation of VEGF and its primary receptor VEGFR2, sensitizing endothelium to the angiogenic signal.
• TB-500 (Thymosin Beta-4) — upregulates VEGF as part of its wound-healing mechanism, complementing its primary actin-sequestration activity; combined BPC-157 + TB-500 stacks target VEGF signaling through two independent upstream mechanisms.
• GHK-Cu — copper tripeptide with evidence of VEGF modulation and broad ECM remodeling effects that support vascular ingrowth into healing tissue.

Common misconceptions

VEGF upregulation is frequently conflated with cancer promotion. While VEGF is required for tumor neovascularization, normal physiological VEGF upregulation in injured tissue is self-limiting, tightly regulated by HIF-1α stabilization that resolves as oxygen tension is restored. There is no clinical evidence that peptide-mediated VEGF upregulation in healthy individuals promotes tumor formation, though this concern is appropriately applied to individuals with known active malignancies.